Wacker

Wacker Chemie AG is a publicly traded industrial leader with a mission to provide innovative, sustainable chemical and biotech solutions globally. Its key achievement is the successful diversification from legacy silicones and polymers into a high-growth, technology-driven biologics CDMO, capturing significant market share in microbial fermentation and nucleic acid manufacturing. The company's strategy leverages its immense scale, process engineering excellence, and integrated technology platform to serve as a critical partner for biopharma companies developing next-generation therapeutics. Financially robust with ~€5.5B in annual sales, Wacker uses this stability to invest in expanding its biotech capabilities and global footprint.

Integrated CDMO platform specializing in microbial fermentation (E. coli) for proteins/plasmids and an end-to-end nucleic acid service from plasmid DNA (pDNA) synthesis to mRNA production and lipid nanoparticle (LNP) formulation.

Wacker Biotech competes with large, diversified CDMOs like Lonza and Catalent in nucleic acids, and specialists like AGC Biologics in microbial fermentation. Its primary competitive advantages are its fully integrated pDNA-to-LNP service offering, unparalleled industrial-scale process engineering from its chemical heritage, and the financial stability of its parent corporation.